Therefore, our data suggest that a subset of CRC tumors with poor prognosis depends on AXL and TGFβ signaling and thus targeted treatment could represent a promising innovative therapeutic strategy for these patients. The gene discussed is AXL; the disease is colorectal carcinoma.